Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) today announces that, as a result of a delay in filing its annual financial statements, the related management’s discussion and analysis and annual information form, and the accompanying chief executive officer and chief financial officer certification for its financial year ended December 31, 2022 (collectively, the “Annual Filing Documents”), the Company will also be delayed in the filing of its financial statements, the related management’s discussion and analysis and the accompanying chief executive officer and chief financial officer certification for its first quarter ended March 31, 2023 (the “Q1 Filing Documents”) and now expects to file the Q1 Filing Documents by June 9, 2023. As announced on May 15, 2023, the Company expects to file the Annual Filing Documents by May 31, 2023.
On March 22, 2023, and as further updated on April 3, 2023, April 17, 2023, May 1, 2023 and May 15, 2023, the Company announced (the “Default Announcement”) that under National Policy 12-203 Management Cease Trade Orders it had applied to the Ontario Securities Commission (the “OSC”) requesting a management cease trade order (“MCTO”) be imposed in respect of the late filing of the Annual Filing Documents. The MCTO was granted by the OSC on April 3, 2023.
The MCTO restricts all trading in and all acquisitions of the securities of the Company, directly or indirectly, by the Chief Executive Officer and the Chief Financial Officer of the Company until two full business days following the receipt by the OSC of the Annual Filing Documents and any other filings the Company is required to make under Ontario securities laws, including the Q1 Filings, or upon the further order of the director of the OSC. The MCTO does not affect the ability of shareholders who are not named in the MCTO to trade their securities.
